Clinical Trial Update: A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating the combination of amivantamab and lazertinib for metastatic or recurrent non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)
• Rybrevant (amivantamab) (amivantamab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED